We are gradually migrating to our new home, the HDR UK Phenotype Library.
CCU002_02 COVID19 vaccination
Metadata
Name | CCU002_02 COVID19 vaccination |
Type | Disease or Syndrome |
Group | Disease or Syndrome |
Data Sources |
|
Clinical Terminologies |
SNOMED-CT |
Codelists | covid_impact_ccu00202_COVID19_vaccine_AstraZeneca_England_SNOMEDCT.csv covid_impact_ccu00202_COVID19_vaccine_dose_England_SNOMEDCT.csv covid_impact_ccu00202_COVID19vaccine_Moderna_England_SNOMEDCT.csv covid_impact_ccu00202_COVID19vaccine_Pfizer_England_SNOMEDCT.csv |
Valid Event Data Range | 08/12/2020 - 18/03/2021 |
Sex |
Female Male |
Authors | CVD-COVID-UK consortium, William N Whiteley, Samantha Ip, Jennifer A Cooper, Thomas Bolton, Spencer Keene, Venexia Walker, Rachel Denholm, Ashley Akbari, Efosa Omigie, Sam Hollings, Emanuele Di Angelantonio, Spiros Denaxas, Angela Wood, Jonathan A C Sterne, Cathie Sudlow |
Agreement Date | 23 Aug 2021 |
Version (UUID) | Revision 1 (COVID-IMPACT) |
Phenotypes
Code type is set to 1 for incident events, and 0 for prevalent events.
England primary care EHR: COVID19 vaccine: AstraZeneca
terminology | code | term | code_type |
---|---|---|---|
SNOMEDCT | 39114911000001105 | COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca UK Ltd) 8 dose (product) | |
SNOMEDCT | 39114911000001105 | COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca UK Ltd) 10 dose (product) | |
SNOMEDCT | 39114911000001105 | COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca UK Ltd) (product) |
England primary care EHR: COVID19 vaccine: dose
terminology | code | term | code_type |
---|---|---|---|
SNOMEDCT | 1324691000000104 | Administration of second dose of severe acute respiratory syndrome coronavirus 2 vaccine (procedure) | |
SNOMEDCT | 1324681000000101 | Administration of first dose of severe acute respiratory syndrome coronavirus 2 vaccine (procedure) |
England primary care EHR: COVID19vaccine: Moderna
terminology | code | term | code_type |
---|---|---|---|
SNOMEDCT | 39326911000001101 | COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials (Moderna, Inc) (product) | |
SNOMEDCT | 39375411000001104 | COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials (Moderna, Inc) 10 dose (product) |
England primary care EHR: COVID19vaccine: Pfizer
terminology | code | term | code_type |
---|---|---|---|
SNOMEDCT | 39115611000001103 | COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials (Pfizer Ltd) (product) | |
SNOMEDCT | 39114911000001105 | COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials (Pfizer Ltd) 6 dose (product) |
Publication
Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, and thrombocytopenic events: whole population cohort study in 46 million adults in England
CVD-COVID-UK consortium, William N Whiteley, Samantha Ip, Jennifer A Cooper, Thomas Bolton, Spencer Keene, Venexia Walker, Rachel Denholm, Ashley Akbari, Efosa Omigie, Sam Hollings, Emanuele Di Angelantonio, Spiros Denaxas, Angela Wood, Jonathan A C Sterne, Cathie Sudlow
medRxiv 2021.08.18.21262222; doi: https://doi.org/10.1101/2021.08.18.21262222